Intraarticular release and accumulation of defensins and bactericidal/permeability-increasing protein in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 30, Issue 8, 2003, Pages 1719-1724

  Bokarewa, Maria I ^a   Jin, Tao ^a   Tarkowski, Andrej ^a  

^a Dept Rheumatol/Inflammation Res ^*

Author keywords

Arthritis; Defensins; Inflammation

Indexed keywords

BACTERICIDAL PERMEABILITY INCREASING PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DEFENSIN; RHEUMATOID FACTOR;

ADULT; AGED; ANTIMICROBIAL ACTIVITY; ARTICLE; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRANULE CELL; HOST; HUMAN; IMMUNE SYSTEM; JOINT EFFUSION; JOINT RADIOGRAPHY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SECRETION; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-DEFENSINS; ANTIMICROBIAL CATIONIC PEPTIDES; ARTHRITIS, RHEUMATOID; BLOOD PROTEINS; FEMALE; HUMANS; JOINTS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; SYNOVIAL FLUID;

EID: 0042530421     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Pillinger MH, Abramson SB. The neutrophil in rheumatoid arthritis. Rheum Dis Clin North Am 1995;21:691-714.
2. Issekutz AC. Adhesion molecules mediating neutrophil migration to arthritis in vivo and across endothelium and connective tissue barriers in vitro. Inflamm Res 1998;47 Suppl 3:S123-32.
3. Prete PE, Gurakar-Osborne A. The contribution of synovial fluid lipoproteins to the chronic synovitis of rheumatoid arthritis. Prostaglandins 1997;54:689-98.
4. Bank U, Ansorge S. More than destructive: neutrophil-derived serine proteases in cytokine bioactivity control. J Leukoc Biol 2001;69:197-206.
5. Ishiguro N, Ito T, Oguchi T, et al. Relationships of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum 2001;44:2503-11.
6. Cunnane G, Fitzgerald O, Beeton C, Cawston TE, Bresnihan B. Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis Rheum 2001;44:2263-74.
7. Ganz T. Defensins and host defense. Science 1999;286:420-1.
8. Levy O. Antimicrobial proteins and peptides of blood: templates for novel antimicrobial agents. Blood 2000;96:2664-72.
9. Hancock RE. Peptide antibiotics. Lancet 1997;349:418-22.
10. Raj PA, Dentino AR. Current status of defensins and their role in innate and adaptive immunity. FEMS Microbiol Lett 2002;206:9-18.
11. Schultz H, Weiss J, Carroll SF, Gross WL. The endotoxin-binding bactericidal/permeability-increasing protein (BPI): a target antigen of autoantibodies. J Leukoc Biol 2001;69:505-12.
12. Wiese A, Brandenburg K, Lindner B, et al. Mechanisms of action of the bactericidal/permeability-increasing protein BPI on endotoxin and phospholipid monolayers and aggregates. Biochemistry 1997;36:10301-10.
13. Bruce C, Chouinard RA Jr, Tall AR. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu Rev Nutr 1998;18:297-330.
14. Dentener MA, Francot GJ, Buurman WA. Bactericidal/permeability-increasing protein, a lipopolysaccharide-specific protein on the surface of human peripheral blood monocytes. J Infect Dis 1996;173:252-5.
15. van den Berg RH, Faber-Krol MC, van Wetering S, Hiemstra PS, Daha MR. Inhibition of activation of the classical pathway of complement by human neutrophil defensins. Blood 1998;92:3898-903.
16. von der Mohlen MA, van der Poll T, Jansen J, Levi M, van Deventer SJ. Release of bactericidal/permeability-increasing protein in experimental endotoxemia and clinical sepsis. Role of tumor necrosis factor. J Immunol 1996;156:4969-73.
17. Uronen H, Williams AJ, Dixon G, et al. Gram-negative bacteria induce proinflammatory cytokine production by monocytes in the absence of lipopolysaccharide. Clin Exp Immunol 2000;122:312-5.
18. Huang K, Fishwild DM, Wu HM, Dedrick RL. Lipopolysaccharide-induced E-selectin expression requires continuous presence of LPS and is inhibited by bactericidal/permeability-increasing protein. Inflammation 1995;19:389-404.
19. van der Schaft DW, Toebes EA, Haseman JR, Mayo KH, Griffioen AW. Bactericidal/permeability-increasing protein (BPI) inhibits angiogenesis via induction of apoptosis in vascular endothelial cells. Blood 2000;96:176-81.
20. Zhang H, Porro G, Orzech N, Mullen B, Liu M, Slutsky AS. Neutrophil defensins mediate acute inflammatory response and lung dysfunction in dose-related fashion. Am J Physiol Lung Cell Mol Physiol 2001;280:L947-54.
21. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
22. Agerberth B, Charo J, Werr J, et al. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000;96:3086-93.
23. Levy O, Martin S, Eichenwald E, et al. Impaired innate immunity in the newborn: newborn neutrophils are deficient in bactericidal/permeability-increasing protein. Pediatrics 1999;104:1327-33.
24. Hubacek JA, Stuber F, Frohlich D, et al. Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: gender-specific genetic predisposition to sepsis. Crit Care Med 2001;29:557-61.
25. Tsuruta T, Tani K, Hoshika A, Asano S. Alkaline phosphatase, defensin gene expression and effect of myeloid cell growth factors in normal and leukemic cells. Leuk Lymphoma 1999;32:237-47.
26. Klut ME, Whalen BA, Hogg JC. Dynamic changes in neutrophil defensins during endotoxemia. Infect Immun 2001;69:7793-9.
27. Halder TM, Bluggel M, Heinzel S, Pawelec G, Meyer HE, Kalbacher H. Defensins are dominant HLA-DR-associated self-peptides from CD34(-) peripheral blood mononuclear cells of different tumor patients (plasmacytoma, chronic myeloid leukemia). Blood 2000;95:2890-6.
28. Barnathan ES, Raghunath PN, Tomaszewski JE, Ganz T, Cines DB, Higazi A-R. Immunohistochemical localization of defensin in human coronary vessels. Am J Pathol 1997;150:1009-20.
29. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002;415:389-95.
30. Tani K, Murphy WJ, Chertov O, et al. Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. Int Immunol 2000;12:691-700.
31. Yang D, Chen Q, Chertov O, Oppenheim JJ. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J Leukoc Biol 2000;68:9-14.
32. Panyutich A, Ganz T. Activated alpha 2-macroglobulin is a principal defensin-binding protein. Am J Respir Cell Mol Biol 1991;5:101-6.
33. Higazi AA, Nassar T, Ganz T, et al. The alpha-defensins stimulate proteoglycan-dependent catabolism of low-density lipoprotein by vascular cells: a new class of inflammatory apolipoprotein and a possible contributor to atherogenesis. Blood 2000;96:1393-8.